Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome
Exagen Inc. (Nasdaq: XGN) announced a collaboration with the Hospital for Special Surgery (HSS) in New York City to conduct a proof-of-concept study focusing on antiphospholipid syndrome (APS). This project aims to investigate complement activation markers and other biomarkers in aPL-positive patients. The partnership reflects Exagen's commitment to enhance research and patient care in autoimmune diseases. The study will be led by Dr. Doruk Erkan at HSS, a top-ranked institution in rheumatology. Exagen continues to develop innovative testing products under its AVISE® brand, targeting various autoimmune disorders.
- Collaboration with HSS enhances research capabilities.
- Focus on antiphospholipid syndrome may lead to innovative treatments.
- Strengthening brand reputation through association with a top medical institution.
- Dependent on success of the proof-of-concept study; financial outcomes uncertain.
- Potential risks in developing new testing products in a competitive market.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a collaboration with Hospital for Special Surgery (HSS) in New York City. This well-respected institution is the world’s leading academic medical center for autoimmune diseases and musculoskeletal health; for 28 consecutive years it has been among the top-ranked hospitals in the nation for rheumatology and orthopedics.
Antiphospholipid syndrome (APS) is an autoimmune clotting disorder which most commonly increases the risk of blood clots and pregnancy complications as a result of antiphospholipid antibodies (aPL). Complement cascade, which is part of the immune system, is involved in the development of aPL-related clinical problems. This proof-of-concept clinical study, led by Doruk Erkan, MD, MPH, rheumatologist at the Barbara Volcker Center for Women and Rheumatic Diseases at HSS, will investigate complement activation markers, and additional biomarkers, in different subgroups of aPL-positive patients.
“We’re pleased to be partnering with HSS. Exagen shares a common goal with HSS to advance the science of rheumatology through research, leading to the highest quality patient care and enhancing the quality of life for all,” said Ron Rocca, President and CEO of Exagen.
For more information about this study, please contact Joann Vega at vegaj@hss.edu or call 212-774-2795.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products (CB-CAPs), technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus (SLE). Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.
About HSS
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report “Best Children’s Hospitals” list (2019-2020). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 130 countries. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, express or implied statements regarding the proof-of-concept collaborative study and potential advancement of our science as it compares to complement activation and other biomarkers in different subgroups of patients with aPL. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the collaboration with HSS may not lead to discoveries that advance Exagen’s science or result in an ability to successfully develop and commercialize a new testing product; and other risks described in the company’s prior press releases and the company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514
FAQ
What is the focus of Exagen's collaboration with HSS?
What are the potential benefits of the study led by Exagen and HSS?
When was the collaboration between Exagen and HSS announced?
What is Exagen's stock symbol?
Who is leading the study at HSS?
